Key Insights

Highlights

Treatment Research

1 treatments under study, led by Mrg002

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04492488Phase 1/2Active Not Recruiting

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Showing all 1 trials

Research Network

Common Treatments

  • Mrg0021

Active Sponsors

  • Shanghai Miracogen Inc.1

Top Investigators

Related Conditions

  • Advanced Solid Tumors1
  • Advanced Or Metastatic Gastric Cancer1

Activity Timeline